Incidence of Fistula Occurrence in Patients with Cervical Cancer Treated with Bevacizumab: Data from Real-world Clinical Practice

International Journal of Clinical Oncology

Toru Sugiyama, MD PhD¹, Noriyuki Katsumata, MD PhD², Takafumi Toita, MD PhD³, Masako Ura, BS⁴, Ayaka Shimizu, BPharm⁵, Shuichi Kamijima, MD PhD⁶, Daisuke Aoki, MD PhD⁷

Correspondence to: Toru Sugiyama, MD PhD

St. Mary’s Hospital, 422 Tsubukuhonmachı,
Kurume, Fukuoka, 830-8543, Japan

Email: sugiyamatoru0802@yahoo.co.jp
### Online Resource Table S1. Information collected from patient records in the case series study

| Major item                                      | Sub-item                                      |
|------------------------------------------------|-----------------------------------------------|
| **Patient background**                          |                                               |
| Smoking history                                 | Presence or absence/details                   |
| Past history and coexisting diseases            | Presence or absence/details                   |
| **Previous surgery before bevacizumab**         |                                               |
| History of surgery                              | Presence or absence                           |
| Surgical procedure                              | Name                                          |
|                                                | Operation time                                |
|                                                | Intraoperative blood loss (mL)                |
| **Radiation therapy/external-beam radiation prior to bevacizumab (at initial treatment)**<sup>a</sup> |                                               |
| External irradiation                            | Presence or absence                           |
| Central shielding                               | Presence or absence                           |
|                                                | If yes, when                                  |
| Radiation therapy (irrespective of central shielding) | Irradiation start date to irradiation end date |
|                                                | Irradiation method                            |
|                                                | Irradiation field                             |
|                                                | X-ray energy                                   |
|                                                | Number of fractions                            |
|                                                | Dose per fraction (Gy)                         |
|                                                | Total dose (Gy)                                |
| **Radiation therapy/intracavitary irradiation before bevacizumab (at initial treatment)** |                                               |
| Intracavitary irradiation<sup>1</sup>           | Presence or absence                           |
|                                                | Irradiation start date to irradiation end date |
|                                                | Dose per fraction (Gy): Point A dose/ HR-CTV D90 |
|                                                | Number of fractions                            |
|                                                | Total dose (Gy):                               |
|                                                | Total rectal dose (Gy): ICRU38/ D2cm<sup>3</sup>|
|                                                | Total bladder dose (Gy): ICRU38/ D2cm<sup>3</sup>|
|                                                | Types of Ovoid Applicators                     |
|                                                | HYBRID brachytherapy: Yes/No                   |
|                                                | If yes, no. of applicators                     |
| **Radiation therapy/interstitial irradiation before administration of bevacizumab (at initial treatment)** |                                               |
| Interstitial irradiation<sup>2</sup>            | Presence or absence                           |
|                                                | Irradiation start date to irradiation end date |
### Radiation therapy for recurrent tumor before bevacizumab

| Radiation therapy** | Presence or absence/details |
|---------------------|-----------------------------|
| For external, intracavitary or interstitial irradiation | Irradiation start date to irradiation end date |
|                     | Overlap with the extent of initial radiation therapy |
|                     | Irradiation method (only in case of external irradiation) |
|                     | Irradiation field (only in case of external irradiation) |
|                     | X-ray energy (only in case of external irradiation) |
|                     | Dose per fraction (Gy) |
|                     | Number of fractions |
|                     | Total dose (Gy) |
| For intracavitary or interstitial irradiation | Total rectal dose (Gy) |
| For intracavitary radiation only | Types of ovoid applicators |
|                     | HYBRID (intra-tissue irradiation applicator added): Yes/no |
|                     | If yes, number of units and site |

### Presence or absence of concurrent chemoradiotherapy (CCRT) prior to bevacizumab

| Concurrent chemoradiotherapy | Presence or absence |
|-----------------------------|---------------------|
|                             | Concomitant drug    |
|                             | Duration of administration |

### Presence or absence of recurrent tumor at the start of bevacizumab

| Recurrent tumor | Presence or absence |
|-----------------|---------------------|
|                 | Site of recurrence  |
|                 | Recurrence date     |
| Recurrent tumor | Presence or absence of recurrent tumor biopsy |

### Immediately before bevacizumab administration

| Before the first dose of bevacizumab or just before the onset of fistula | Date of inspection |
|                                                                         | Hemoglobin (g/dL)  |
|                                                                         | Platelet ($\times 10^9$/mm$^3$) |
|                                                                         | Albumin (g/dL)      |
| Creatinine (mg/dL) | HbA1c (%) | CRP (mg/dL) | Urine protein (dipstick method) |
|-------------------|-----------|-------------|-----------------------------|

### Information about bevacizumab combination chemotherapy

| Number of bevacizumab-treated cycles | Number of bevacizumab-treated cycles |
|-------------------------------------|-------------------------------------|
| Tumor shrinkage effect              | Response                            |

### Information about the fistula

| Diagnostic information | Diagnostic method |
|------------------------|-------------------|
|                        | Date of diagnosis |

| Additional measures for fistulas | Presence or absence |
|---------------------------------|---------------------|
|                                 | Details and date of treatment |

| Current outcome of fistula | Date of outcome |
|----------------------------|-----------------|
|                            | Outcome         |

### Patient outcome information

| Treatment of cervical cancer after fistula | Presence or absence |
|-------------------------------------------|---------------------|
|                                            | Treatment content   |
|                                            | Duration of treatment |

| Survival | Outcome |
|----------|---------|
|          | Confirmation date (last survival confirmation date or death date) |

*The digitally reconstructed radiographs and dose distribution map for each radiation treatment was requested.*

CRP, C-reactive protein; HbA1c, glycated hemoglobin; HRCTV, high-risk clinical target volume; ICRU, International Commission on Radiation Units & Measurements.